Original

Safety and tolerability in the early phase of slow schedule versus fast schedule treatment with 44 micrograms of interferon beta-1a in patients with multiple sclerosis (PARALEN study)

M.Á. Hernández, en representación del grupo de investigadores del estudio PARALEN [REV NEUROL 2009;48:505-508] PMID: 19434583 DOI: https://doi.org/10.33588/rn.4810.2008423

OPEN ACCESS

Volumen 48 | Number 10 | Nº of views of the article 5.267 | Nº of PDF downloads 690 | Article publication date 14/05/2009

Download PDF Castellano Citation Search in PubMed

Share in:

Go to another issue

ABSTRACT

INTRODUCTION Interferon (IFN) beta-1a, 44 micrograms, administered three times a week (tiw), is the recommended dose in ‘relapsing’ multiple sclerosis. During the clinical practice, physicians initiate treatment either with this complete dose, or with escalating dose.

AIM To determine safety of IFN beta-1a 44 micrograms tiw, comparing a complete dose initiation regimen versus an escalating dose initiation.

PATIENTS AND METHODS A total of 247 multiple sclerosis patients were enrolled in this study from 37 different Spanish centers, who initiated treatment with IFN beta-1a 44 micrograms tiw. Safety and tolerability was compared in patients switching from other previous interferon to a direct complete dose regime of IFN beta-1a 44 micrograms tiw vs. an escalating dose regime in naïve multiple sclerosis patients.

RESULTS Adverse events were more frequent when administrating interferon in a ‘fast-regime’ directly with a complete dose.

CONCLUSIONS An escalating dose with IFN beta-1a 44 micrograms tiw is recommended to initiate treatment in multiple sclerosis patients. In patients previously treated with another interferon beta, a complete dose regime initiation can be also scheduled, without significant differences in the reporting of adverse events. KeywordsDemyelinating disease Escalating dose Immunomodulatory Interferon beta-1a Multiple sclerosis Observational study Treatment

FULL TEXT (solo disponible en lengua castellana / Only available in Spanish)

Acceso directo al último número

Último Podcast

Original

Safety and tolerability in the early phase of slow schedule versus fast schedule treatment with 44 micrograms of interferon beta-1a in patients with multiple sclerosis (PARALEN study)

¡CONVIÉRTASE EN USUARIO PREMIUM DE NEUROLOGIA.COM!

Al hacerse premium, está apoyándonos para que Revista de Neurología siga siendo uno de los referentes de habla hispana en la difusión del conocimiento en neurociencias. ¡Gratuita tanto para autores como para todos los usuarios de la web!